Vor Biopharma price to book ratio VOR

Market value divided by the book value of the company's net assets, since 2021.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 3.9×; Aug 2025
5-year median: 1.0×
5-year range: 0.2× to 4.7×
Peer median: 5.3×

Vor Biopharma's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Aug 2025, at 3.9×.

On the days it had one over the last 5 years, its median was 1.0×, from 0.2× in May 2025 to 4.7× in Jul 2025.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	3.9×	0.2×	4.7×
2024	1.2×	0.5×	1.2×
2023	0.9×	0.6×	1.6×
2022	1.6×	0.8×	1.7×
2021	1.9×	1.7×	3.4×

Against its peers

Companies in Biotechnology nearest Vor Biopharma's size, closest first, today.

Company	Price to book ratio
VORVor Biopharma	n/m
MGTXMeiraGTx	4.1×
VCELVericel	5.9×
ADMAAdma Biologics	5.9×
PLXProtalix BioTherapeutics	2.9×
KRYSKrystal Biotech	6.8×
RGENRepligen	4.7×
Peer median	5.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Vor Biopharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.